Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Rehasport Clinic
Modality
Cell therapy
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04321629CT.gov Knee Arthritis Treatment With Autologous Fragmented Adipose Tissue and PRP - Comparison of Two Treatment Methods | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Arthropathy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Human Autologous Adipose Tissue (this asset) | Rehasport Clinic | P2 | CCC · 53 |
| Diclofenac | Express Specialty Pharmacy | P4 | BBB |
| Propofol | Pedro Paulo Tanaka | P4 | BB |
| Desflurane | Pedro Paulo Tanaka | P4 | BB |
| Testosterone Undecylate | Alliance for Clinical Trials in Oncology | P3 | BB |
| Letrozole | ARKAY Therapeutics | P2 | BB |
| Gabapentin | British Columbia Cancer Agency | P2/3 | B |
| Calcarea Gluconica | University of Washington | P2 | B |
| Oxycodone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P2 | CCC |
+24 more in the Arthropathy cohort
Other indications for Human Autologous Adipose Tissue
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Osteoarthritis, Knee | — | P2 | CCC · 53 |
| Shoulder Impingement Syndrome | — | Early P1 | C · 39 |
| Rotator Cuff Syndrome | — | Early P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Human Autologous Adipose Tissue in Arthropathy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/human-autologous-adipose-tissue-arthropathy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →